Wed, July 8, 2020
Tue, July 7, 2020
Mon, July 6, 2020

Paul Matteis Upgraded (ACAD) to Strong Buy and Increased Target to $71 on, Jul 7th, 2020

Paul Matteis of Stifel, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Increased Target from $41 to $71 on, Jul 7th, 2020.

Paul has made no other calls on ACAD in the last 4 months.



There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $53 on, Wednesday, May 27th, 2020


These are the ratings of the 3 analyists that currently disagree with Paul


  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $63 on, Friday, May 8th, 2020
  • Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $60 on, Thursday, April 16th, 2020
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $72 on, Tuesday, March 31st, 2020